- Home
- TENX vs SBFM Comparison
TENX vs SBFM Comparison
Compare TENX & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- SBFM
- Stock Information
- Founded
- TENX 1967
- SBFM 2006
- Country
- TENX United States
- SBFM United States
- Employees
- TENX N/A
- SBFM N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- SBFM Health Care
- Exchange
- TENX Nasdaq
- SBFM Nasdaq
- Market Cap
- TENX 11.4M
- SBFM 3.7M
- IPO Year
- TENX N/A
- SBFM N/A
- Fundamental
- Price
- TENX $3.90
- SBFM $3.00
- Analyst Decision
- TENX Strong Buy
- SBFM
- Analyst Count
- TENX 3
- SBFM 0
- Target Price
- TENX $23.00
- SBFM N/A
- AVG Volume (30 Days)
- TENX 33.0K
- SBFM 153.8K
- Earning Date
- TENX 11-11-2024
- SBFM 11-11-2024
- Dividend Yield
- TENX N/A
- SBFM N/A
- EPS Growth
- TENX N/A
- SBFM N/A
- EPS
- TENX N/A
- SBFM N/A
- Revenue
- TENX N/A
- SBFM $30,481,982.00
- Revenue This Year
- TENX N/A
- SBFM $86.70
- Revenue Next Year
- TENX N/A
- SBFM $126.76
- P/E Ratio
- TENX N/A
- SBFM N/A
- Revenue Growth
- TENX N/A
- SBFM 109.82
- 52 Week Low
- TENX $2.77
- SBFM $2.42
- 52 Week High
- TENX $61.20
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- TENX 61.96
- SBFM 46.45
- Support Level
- TENX $3.30
- SBFM $2.85
- Resistance Level
- TENX $3.95
- SBFM $3.05
- Average True Range (ATR)
- TENX 0.20
- SBFM 0.15
- MACD
- TENX 0.07
- SBFM 0.02
- Stochastic Oscillator
- TENX 90.28
- SBFM 43.59
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.